Animal Pharm is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India reduces pet food customs duty:

India has reduced the customs duty on pet foods from 30% to 20%, terming the reduction as "good news for cat and dog lovers". This is part of budget proposals put forward by finance minister P Chidambaram for 2007-08. However, the announcement drew some flak from the "opposition hounds", according to some media reports. The Indian companion animal segment has emerged as one of the fastest-growing segments in the industry, registering growth of 19% per year. Elsewhere, Mr Chidambaram has restricted the tax exemption on the income of a venture capital company or fund involved in nanotechnology, biotechnology, the dairy industry, the poultry industry, R&D of new chemical entities in the pharmaceutical sectors and some other specific areas. "Since such funds enjoy a pass-through status, it is necessary to limit the tax benefit to investments made in truly deserving sectors," said Mr Chidambaram. This amendment is effective from April 1st, 2008.

Topics

What to read next

UsernamePublicRestriction

Register

AP006588

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel